Top

Published in:

Open Access 01-12-2012 | Research article

TGFB1 genetic polymorphisms and coronary heart disease risk: a meta-analysis

Authors: Yingchang Lu, Jolanda MA Boer, Roza M Barsova, Olga Favorova, Anuj Goel, Michael Müller, Edith JM Feskens, and on behalf of PROCARDIS CARDIoGRAM Consortium

Published in: BMC Medical Genetics | Issue 1/2012

Abstract

Background

Genetic variations in TGFB1 gene have been studied in relation to coronary heart disease (CHD) risk, but the results were inconsistent.

Methods

We performed a systematic review of published studies on the potential role of TGFB1 genetic variation in CHD risk. Articles that reported the association of TGFB1 genetic variants with CHD as primary outcome were searched via Medline and HuGE Navigator through July 2011. The reference lists from included articles were also reviewed.

Results

Data were available from 4 studies involving 1777 cases and 7172 controls for rs1800468, 7 studies involving 5935 cases and 10677 controls for rs1800469, 7 studies involving 6634 cases and 9620 controls for rs1982073, 5 studies involving 5452 cases and 9999 controls for rs1800471, and 4 studies involving 5143 cases and 4229 controls for rs1800472. The pooled odds ratios (ORs) for CHD among minor T allele carriers of rs1800469, minor C allele carriers of rs1982073, and minor C allele carriers of rs1800471 versus homozygous major allele carriers was 1.14 (95% confidence interval [CI]: 1.05-1.24), 1.18 (95% CI: 1.04-1.35), and 1.16 (95% CI: 1.02-1.32), respectively. No substantial heterogeneity for ORs was detected among the included Caucasian populations for all SNPs. However, for rs1800471, the statistical significance disappeared after adjusting for potential publication bias. No significant association was found between rs1800468 and rs1800472 variants and CHD risk.

Conclusion

Minor allele carriers of two genetic variants (rs1800469 and rs1982073) in TGFB1 have a 15% increased risk of CHD.

Available only for authorised users

Pardali E, Goumans MJ, ten Dijke P: Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends Cell Biol. 2010, 20 (9): 556-567. 10.1016/j.tcb.2010.06.006.CrossRefPubMed

Khan R, Agrotis A, Bobik A: Understanding the role of transforming growth factor-beta1 in intimal thickening after vascular injury. Cardiovasc Res. 2007, 74 (2): 223-234. 10.1016/j.cardiores.2007.02.012.CrossRefPubMed

Schulick AH, Taylor AJ, Zuo W, Qiu CB, Dong G, Woodward RN, Agah R, Roberts AB, Virmani R, Dichek DA: Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc Natl Acad Sci U S A. 1998, 95 (12): 6983-6988. 10.1073/pnas.95.12.6983.CrossRefPubMedPubMedCentral

Suthanthiran M, Li B, Song JO, Ding R, Sharma VK, Schwartz JE, August P: Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A. 2000, 97 (7): 3479-3484.PubMedPubMedCentral

Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA: Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest. 1991, 88 (3): 904-910. 10.1172/JCI115393.CrossRefPubMedPubMedCentral

Frutkin AD, Otsuka G, Stempien-Otero A, Sesti C, Du L, Jaffe M, Dichek HL, Pennington CJ, Edwards DR, Nieves-Cintron M, et al: TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2009, 29 (9): 1251-1257. 10.1161/ATVBAHA.109.186593.CrossRefPubMedPubMedCentral

Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L: Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest. 1992, 90 (4): 1582-1592. 10.1172/JCI116027.CrossRefPubMedPubMedCentral

Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, et al: Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A. 1993, 90 (22): 10759-10763. 10.1073/pnas.90.22.10759.CrossRefPubMedPubMedCentral

Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A: The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med. 1995, 1 (1): 74-79. 10.1038/nm0195-74.CrossRefPubMed

10.

Wang XL, Sim AS, Wilcken DE: A common polymorphism of the transforming growth factor-beta1 gene and coronary artery disease. Clin Sci (Lond). 1998, 95 (6): 745-746. 10.1042/CS19980292.CrossRef

11.

Najar RA, Ghaderian SM, Panah AS: Association of Transforming Growth Factor-beta1 Gene Polymorphisms With Genetic Susceptibility to Acute Myocardial Infarction. Am J Med Sci. 2011, 342 (5): 365-370. 10.1097/MAJ.0b013e318215908a.CrossRefPubMed

12.

McCaffrey TA, Consigli S, Du B, Falcone DJ, Sanborn TA, Spokojny AM, Bush HL: Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1. J Clin Invest. 1995, 96 (6)): 2667-2675.CrossRefPubMedPubMedCentral

13.

Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, Loch D, Carlson OD, Griswold BF, Fu Q, De Backer J, et al: Circulating transforming growth factor-beta in Marfan syndrome. Circulation. 2009, 120 (6): 526-532. 10.1161/CIRCULATIONAHA.108.841981.CrossRefPubMedPubMedCentral

14.

Syrris P, Carter ND, Metcalfe JC, Kemp PR, Grainger DJ, Kaski JC, Crossman DC, Francis SE, Gunn J, Jeffery S, et al: Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. Clin Sci (Lond). 1998, 95 (6): 659-667.CrossRef

15.

Yamada Y, Miyauchi A, Goto J, Takagi Y, Okuizumi H, Kanematsu M, Hase M, Takai H, Harada A, Ikeda K: Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res. 1998, 13 (10): 1569-1576.CrossRefPubMed

16.

Cambien F, Ricard S, Troesch A, Mallet C, Generenaz L, Evans A, Arveiler D, Luc G, Ruidavets JB, Poirier O: Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension. 1996, 28 (5)): 881-887.CrossRefPubMed

17.

Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD: Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet. 1999, 8 (1): 93-97. 10.1093/hmg/8.1.93.CrossRefPubMed

18.

Shah R, Rahaman B, Hurley CK, Posch PE: Allelic diversity in the TGFB1 regulatory region: characterization of novel functional single nucleotide polymorphisms. Hum Genet. 2006, 119 (1–2): 61-74.CrossRefPubMed

19.

Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V, et al: A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res. 2003, 63 (10): 2610-2615.PubMed

20.

Koch W, Hoppmann P, Mueller JC, Schomig A, Kastrati A: Association of transforming growth factor-beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. Arterioscler Thromb Vasc Biol. 2006, 26 (5): 1114-1119. 10.1161/01.ATV.0000217747.66517.11.CrossRefPubMed

21.

Sie MP, Uitterlinden AG, Bos MJ, Arp PP, Breteler MM, Koudstaal PJ, Pols HA, Hofman A, van Duijn CM, Witteman JC: TGF-beta 1 polymorphisms and risk of myocardial infarction and stroke: the Rotterdam Study. Stroke. 2006, 37 (11): 2667-2671. 10.1161/01.STR.0000244779.30070.1a.CrossRefPubMed

22.

Crobu F, Palumbo L, Franco E, Bergerone S, Carturan S, Guarrera S, Frea S, Trevi G, Piazza A, Matullo G: Role of TGF-beta1 haplotypes in the occurrence of myocardial infarction in young Italian patients. BMC Med Genet. 2008, 9: 13-CrossRefPubMedPubMedCentral

23.

Yokota M, Ichihara S, Lin TL, Nakashima N, Yamada Y: Association of a T29– > C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation. 2000, 101 (24): 2783-2787. 10.1161/01.CIR.101.24.2783.CrossRefPubMed

24.

Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, et al: Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011, 43 (4): 333-338. 10.1038/ng.784.CrossRefPubMedPubMedCentral

25.

A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Nat Genet. 2011, 43 (4)): 339-344.

26.

Sethupathy P, Collins FS: MicroRNA target site polymorphisms and human disease. Trends in genetics: TIG. 2008, 24 (10): 489-497. 10.1016/j.tig.2008.07.004.CrossRefPubMed

27.

Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, Duffy D, Thompson J, Hall I, Kaufman J, Leung TF, et al: Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol. 2005, 162 (3): 201-211. 10.1093/aje/kwi184.CrossRefPubMed

28.

Marchini J, Howie B: Genotype imputation for genome-wide association studies. Nat Rev Genet. 2010, 11 (7): 499-511. 10.1038/nrg2796.CrossRefPubMed

29.

Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000, 56 (2): 455-463. 10.1111/j.0006-341X.2000.00455.x.CrossRefPubMed

30.

Viechtbauer W: Conducting meta-analyses in R with the metafor package. Journal of Statistical Software. 2010, 36 (3): 1-48.CrossRef

31.

Wang Y, Luk AO, Ma RC, So WY, Tam CH, Ng MC, Yang X, Baum L, Lam V, Tong PC, et al: Independent predictive roles of eotaxin Ala23Thr, paraoxonase 2 Ser311Cys and beta-adrenergic receptor Trp64Arg polymorphisms on cardiac disease in Type 2 Diabetes–an 8-year prospective cohort analysis of 1297 patients. Diabet Med. 2010, 27 (4): 376-383. 10.1111/j.1464-5491.2010.02980.x.CrossRefPubMed

32.

Rao M, Guo D, Jaber BL, Tighiouart H, Pereira BJ, Balakrishnan VS: Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in hemodialysis patients. Kidney Int. 2004, 66 (1): 419-427. 10.1111/j.1523-1755.2004.00748.x.CrossRefPubMed

33.

Manginas A, Tsiavou A, Chaidaroglou A, Giamouzis G, Degiannis D, Panagiotakos D, Cokkinos DV: Inflammatory cytokine gene variants in coronary artery disease patients in Greece. Coron Artery Dis. 2008, 19 (8): 575-582. 10.1097/MCA.0b013e32831286e8.CrossRefPubMed

34.

Oda K, Tanaka N, Arai T, Araki J, Song Y, Zhang L, Kuchiba A, Hosoi T, Shirasawa T, Muramatsu M, et al: Polymorphisms in pro- and anti-inflammatory cytokine genes and susceptibility to atherosclerosis: a pathological study of 1503 consecutive autopsy cases. Hum Mol Genet. 2007, 16 (6): 592-599.CrossRefPubMed

35.

Wang Y, Fu W, Xie F, Chu X, Wang H, Shen M, Sun W, Lei R, Yang L, Wu H, et al: Common polymorphisms in ITGA2, PON1 and THBS2 are associated with coronary atherosclerosis in a candidate gene association study of the Chinese Han population. J Hum Genet. 2010, 55 (8): 490-494. 10.1038/jhg.2010.53.CrossRefPubMed

36.

Sudomoina MA, Sukhinina TS, Barsova RM, Favorov AV, Shakhnovich RM, Titov BV, Matveeva NA, Rybalkin IN, Vlasik TN, Ochs MF, et al: Complex analsis of association of inflammation genes with myocardial infarction. Mol Biol (Mosk). 2010, 44 (3): 463-471.CrossRef

37.

Drenos F, Talmud PJ, Casas JP, Smeeth L, Palmen J, Humphries SE, Hingorani AD: Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk. Hum Mol Genet. 2009, 18 (12): 2305-2316. 10.1093/hmg/ddp159.CrossRefPubMedPubMedCentral

38.

Bobik A, Agrotis A, Kanellakis P, Dilley R, Krushinsky A, Smirnov V, Tararak E, Condron M, Kostolias G: Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions, Colocalization implicates TGF-beta in fibrofatty lesion development. Circulation. 1999, 99 (22): 2883-2891. 10.1161/01.CIR.99.22.2883.CrossRefPubMed

39.

Piao M, Tokunaga O: Significant expression of endoglin (CD105), TGFbeta-1 and TGFbeta R-2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb. 2006, 13 (2): 82-89. 10.5551/jat.13.82.CrossRefPubMed

40.

Panutsopulos D, Papalambros E, Sigala F, Zafiropoulos A, Arvanitis DL, Spandidos DA: Protein and mRNA expression levels of VEGF-A and TGF-beta1 in different types of human coronary atherosclerotic lesions. Int J Mol Med. 2005, 15 (4): 603-610.PubMed

41.

O'Brien ER, Bennett KL, Garvin MR, Zderic TW, Hinohara T, Simpson JB, Kimura T, Nobuyoshi M, Mizgala H, Purchio A, et al: Beta ig-h3, a transforming growth factor-beta-inducible gene, is overexpressed in atherosclerotic and restenotic human vascular lesions. Arterioscler Thromb Vasc Biol. 1996, 16 (4): 576-584. 10.1161/01.ATV.16.4.576.CrossRefPubMed

42.

McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, et al: A common allele on chromosome 9 associated with coronary heart disease. Science. 2007, 316 (5830): 1488-1491. 10.1126/science.1142447.CrossRefPubMedPubMedCentral

43.

Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Jonasdottir A, Sigurdsson A, Baker A, Palsson A, et al: A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007, 316 (5830): 1491-1493. 10.1126/science.1142842.CrossRefPubMed

44.

Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T, Braund P, Wichmann HE, et al: Genomewide association analysis of coronary artery disease. N Engl J Med. 2007, 357 (5): 443-453. 10.1056/NEJMoa072366.CrossRefPubMedPubMedCentral

45.

Angelakopoulou A, Shah T, Sofat R, Shah S, Berry DJ, Cooper J, Palmen J, Tzoulaki I, Wong A, Jefferis BJ, et al: Comparative analysis of genome-wide-association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. Eur Heart J. 2011, 3: 1-2.

46.

Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987, 316 (22): 1371-1375. 10.1056/NEJM198705283162204.CrossRefPubMed

47.

McPherson DD, Sirna SJ, Hiratzka LF, Thorpe L, Armstrong ML, Marcus ML, Kerber RE: Coronary arterial remodeling studied by high-frequency epicardial echocardiography: an early compensatory mechanism in patients with obstructive coronary atherosclerosis. J Am Coll Cardiol. 1991, 17 (1): 79-86. 10.1016/0735-1097(91)90707-G.CrossRefPubMed

48.

Stiel GM, Stiel LS, Schofer J, Donath K, Mathey DG: Impact of compensatory enlargement of atherosclerotic coronary arteries on angiographic assessment of coronary artery disease. Circulation. 1989, 80 (6): 1603-1609. 10.1161/01.CIR.80.6.1603.CrossRefPubMed

49.

Hermiller JB, Tenaglia AN, Kisslo KB, Phillips HR, Bashore TM, Stack RS, Davidson CJ: In vivo validation of compensatory enlargement of atherosclerotic coronary arteries. Am J Cardiol. 1993, 71 (8): 665-668. 10.1016/0002-9149(93)91007-5.CrossRefPubMed

50.

Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM: Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation. 2000, 101 (6): 598-603. 10.1161/01.CIR.101.6.598.CrossRefPubMed

51.

Okura H, Kobayashi Y, Sumitsuji S, Terashima M, Kataoka T, Masutani M, Ohyanagi M, Shimada K, Taguchi H, Yasuga Y, et al: Effect of culprit-lesion remodeling versus plaque rupture on three-year outcome in patients with acute coronary syndrome. Am J Cardiol. 2009, 103 (6): 791-795. 10.1016/j.amjcard.2008.11.030.CrossRefPubMed

52.

Fischer M, Broeckel U, Holmer S, Baessler A, Hengstenberg C, Mayer B, Erdmann J, Klein G, Riegger G, Jacob HJ, et al: Distinct heritable patterns of angiographic coronary artery disease in families with myocardial infarction. Circulation. 2005, 111 (7): 855-862. 10.1161/01.CIR.0000155611.41961.BB.CrossRefPubMed

53.

Nishioka T, Nagai T, Luo H, Kitamura K, Hakamata N, Akanuma M, Katsushika S, Uehata A, Takase B, Isojima K, et al: Coronary remodeling of proximal and distal stenotic atherosclerotic plaques within the same artery by intravascular ultrasound study. Am J Cardiol. 2001, 87 (4): 387-391. 10.1016/S0002-9149(00)01388-6.CrossRefPubMed

54.

Helgadottir A, Thorleifsson G, Magnusson KP, Gretarsdottir S, Steinthorsdottir V, Manolescu A, Jones GT, Rinkel GJ, Blankensteijn JD, Ronkainen A, et al: The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008, 40 (2): 217-224. 10.1038/ng.72.CrossRefPubMed

55.

Biros E, Cooper M, Palmer LJ, Walker PJ, Norman PE, Golledge J: Association of an allele on chromosome 9 and abdominal aortic aneurysm. Atherosclerosis. 2010, 212 (2): 539-542. 10.1016/j.atherosclerosis.2010.06.015.CrossRefPubMedPubMedCentral

56.

Thompson AR, Golledge J, Cooper JA, Hafez H, Norman PE, Humphries SE: Sequence variant on 9p21 is associated with the presence of abdominal aortic aneurysm disease but does not have an impact on aneurysmal expansion. Eur J Hum Genet. 2009, 17 (3): 391-394. 10.1038/ejhg.2008.196.CrossRefPubMed

57.

Yasuno K, Bilguvar K, Bijlenga P, Low SK, Krischek B, Auburger G, Simon M, Krex D, Arlier Z, Nayak N, et al: Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet. 2010, 42 ((5): 420-425.CrossRefPubMedPubMedCentral

58.

Nakaoka H, Takahashi T, Akiyama K, Cui T, Tajima A, Krischek B, Kasuya H, Hata A, Inoue I: Differential effects of chromosome 9p21 variation on subphenotypes of intracranial aneurysm: site distribution. Stroke. 2010, 4 (8): 1593-1598.CrossRef

59.

Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, et al: Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006, 312 (5770): 117-121. 10.1126/science.1124287.CrossRefPubMedPubMedCentral

60.

Shimizu C, Jain S, Davila S, Hibberd ML, Lin KO, Molkara D, Frazer JR, Sun S, Baker AL, Newburger JW, et al: Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ Cardiovasc Genet. 2011, 4 (1): 16-25. 10.1161/CIRCGENETICS.110.940858.CrossRefPubMed

61.

Pannu H, Fadulu VT, Chang J, Lafont A, Hasham SN, Sparks E, Giampietro PF, Zaleski C, Estrera AL, Safi HJ, et al: Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation. 2005, 112 (4): 513-520. 10.1161/CIRCULATIONAHA.105.537340.CrossRefPubMed

62.

Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, Meyers J, Leitch CC, Katsanis N, Sharifi N, et al: A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005, 37 (3): 275-281. 10.1038/ng1511.CrossRefPubMed

63.

van de Laar IM, Oldenburg RA, Pals G, Roos-Hesselink JW, de Graaf BM, Verhagen JM, Hoedemaekers YM, Willemsen R, Severijnen LA, Venselaar H, et al: Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet. 2011, 43 (2): 121-126. 10.1038/ng.744.CrossRefPubMed

64.

Prakash SK, LeMaire SA, Guo DC, Russell L, Regalado ES, Golabbakhsh H, Johnson RJ, Safi HJ, Estrera AL, Coselli JS, et al: Rare copy number variants disrupt genes regulating vascular smooth muscle cell adhesion and contractility in sporadic thoracic aortic aneurysms and dissections. Am J Hum Genet. 2010, 87 (6): 743-756. 10.1016/j.ajhg.2010.09.015.CrossRefPubMedPubMedCentral

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/13/39/prepub

Title: TGFB1 genetic polymorphisms and coronary heart disease risk: a meta-analysis
Authors: Yingchang Lu
Jolanda MA Boer
Roza M Barsova
Olga Favorova
Anuj Goel
Michael Müller
Edith JM Feskens
and on behalf of PROCARDIS CARDIoGRAM Consortium
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Medical Genetics / Issue 1/2012
Electronic ISSN: 1471-2350
DOI: https://doi.org/10.1186/1471-2350-13-39

Keynote webinar | Spotlight on medication adherence

Springer Medicine

TGFB1 genetic polymorphisms and coronary heart disease risk: a meta-analysis

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population

A genome wide association study of pulmonary tuberculosis susceptibility in Indonesians

A mutation at IVS1 + 5 of the von Hippel-Lindau gene resulting in intron retention in transcripts is not pathogenic in a patient with a tongue cancer?: case report

High resolution melting: improvements in the genetic diagnosis of hypertrophic cardiomyopathy in a Portuguese cohort

Systems analysis of inflammatory bowel disease based on comprehensive gene information

Frank-ter Haar syndrome associated with sagittal craniosynostosis and raised intracranial pressure